Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer

Kodama, Hirotake; Narita, Shintaro; Takahashi, Masahiro; Sakurai, Toshihiko; Kawamura, Sadafumi; Hoshi, Senji; Ishida, Masanori; Kawaguchi, Toshiaki; Ishidoya, Shigeto; Shimoda, Jiro; Narita, Takuma; Sato, Hiromi; Mitsuzuka, Koji; Tochigi, Tatsuo; Tsuchiya, Norihiko; Arai, Yoichi; Habuchi, Tomonori; Οhyama, Chikara

doi:10.1016/j.clgc.2019.05.029

Cited by 6 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRPC-free survival was significantly shorter in the PSA ≥ 100 group than in PSA < 100 group in patients treated with ADT. However, the OS after CRPC diagnosis was significantly shorter in the PSA < 100 group indicating it might be a poor prognostic factor in CRPC patients [59]. PSA decline of > 50% proved significantly associated with better OS (20.1 months vs 10.5) and PFS (17.9 months vs 6.6 months) following treatment with 225 Ac-PSMA-617 over PSA decline < 50% [60].…”

Section: Psa and Psa Kineticsmentioning

confidence: 91%

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

et al. 2020

View full text Add to dashboard Cite

Background: Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current biomarkers is difficult and often results in unnecessary invasive procedures as well as over-diagnosis and over-treatment. There are a number of prognostic biomarkers for CRPC, but there are no validated predictive biomarkers to guide in clinical decision-making. Specific biomarkers are needed that enable to understand the natural history and complex biology of this heterogeneous malignancy, identify early response to treatment outcomes and to identify the population of men most likely to benefit from the treatment. In this systematic review, we discuss the existing literature for the role of biomarkers in CRPC and how they aid in the prognosis, treatment selection and survival outcomes. Methods: We performed a literature search on PubMed and EMBASE databases from January 2015 through February 2020 in accordance to Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Articles were assessed to identify relevant observational studies and randomized controlled trials regarding biomarkers which aid in identifying progression to mCRPC as well as predictive biomarkers which help in treatment selection. Results: We identified 3640 number of hits of which 58 articles were found to be relevant. Here we addressed biomarkers in the context of prognosis, prediction and patient selection of therapy. These biomarkers were found to be effective as prognostic or predictive factors under variety of conditions. The higher levels for all these biomarkers were associated with shorter median OS and sometimes PFS. Lower amounts of biomarkers in serum or urine were associated with prolonged survival outcomes, longer time to CRPC development or CRPC progression and longer median follow-up irrespective of any therapy. Conclusion: We observed that the biomarkers included in our study predicted clinically relevant survival outcomes and treatment exposure. Though the current biomarkers are prognostic when measured prior to initiating treatment, not all are validated as predictive markers in post treatment setting. A greater understanding of biomarkers in CRPC is need of the hour for development of more personalized approach to maximize benefit and minimize harm in men with CRPC.

show abstract

Section: Psa and Psa Kineticsmentioning

confidence: 91%

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the USA and Europe, PCa accounts for the second most leading cause of cancer-related mortality [6][7]. Although the testing of PSA was generally used in the early diagnosis, the incidence and mortality rate of PCa are still increasing [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway

et al. 2021

View full text Add to dashboard Cite

Background Recently, basic leucine zipper and the W2 domain-containing protein 1 (BZW1) is reported to be implicated in tumor progression. However, the role of BZW1 in prostate cancer remains unknown. This study is aimed to investigate the expression of BZW1 and its in uence on cell proliferation in prostate cancer.Methods The expression levels of BZW1 were measured in 136 cases of prostate cancer and matched adjacent non-cancerous prostate tissues by quanti cational real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). Then, the effect of BZW1 on cell proliferation was further explored.Results QRT-PCR analysis shown that the mRNA levels of BZW1 in prostate cancer were signi cantly greater compared with those in matched adjacent non-cancerous prostate tissues (P<0.001). IHC results shown the high-expression rate of BZW1 in prostate cancer and matched adjacent non-cancerous prostate tissues were 68.4% and 32.4%, and the difference was statistically signi cant (P<0.001). BZW1 high-expression signi cantly correlated with T stage, lymph node metastasis, prostate speci c antigen (PSA) and Gleason score (P<0.05). Patients with BZW1 high-expression presented unfavorable prognosis compared with those with BZW1 low-expression (P=0.002). In addition, CCK-8 and Colony formation assays revealed that BZW1 over-expression signi cantly promoted cell proliferation in vitro. Tumor xenograft shown BZW1 knockdown signi cantly inhibited tumor growth in vivo. Moreover, BZW1 overexpression activated the TGF-β1/Smad1/Smad3 pathway. Conclusion BZW1 over-expression predicts poorer prognosis and promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway.

show abstract

“…The application of the prostate-specific antigen (PSA) test has greatly improved the diagnosis and treatment of PC (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). However, PSA has become associated with the overdiagnosis of patients with the non-aggressive disease and displays limited usefulness in patients with castrationresistant PC (5,(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37). Therefore, there is an unmet need for novel diagnostic (detection of early-stage disease, and differentiation of benign from malignant disease), prognostic (prediction of disease outcome and monitoring of disease recurrence), and predictive (monitoring of the response to therapeutics and aiding treatment decisions) biomarkers.…”

Section: Introductionmentioning

confidence: 99%

Narrative review of urinary glycan biomarkers in prostate cancer

Hatakeyama¹,

Yoneyama²,

Tobisawa³

et al. 2021

Transl Androl Urol

Self Cite

View full text Add to dashboard Cite

Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer

Cited by 6 publications

References 36 publications

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway

Narrative review of urinary glycan biomarkers in prostate cancer

Contact Info

Product

Resources

About